Where is Zendal located?

Zendal is headquartered in Porrino, Spain.

How many employees does Zendal have?

As of Jul 31, 2026, the latest employee count at Zendal is 253.

Where does Zendal rank among its competitors?

Zendal ranks 43rd amongst 1077 active competitors, of which 70 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caidya, which secured $165M in Jan, 2025.

Who are the top competitors of Zendal?

Zendal's top competitors include WuXi AppTec, ANI Pharmaceuticals and EVERSANA. Among them, Caidya secured the most recent funding round in January, 2025.

Zendal - 2026 Company Profile & Competitors

Zendal is an unfunded company based in Porrino (Spain), founded in 2018. It operates as a Provider of drug research & development and marketing of pharmaceutical industry. Zendal has not raised any funding yet. The company has 1077 active competitors, including 70 funded and 127 that have exited. Its top competitors include companies like WuXi AppTec, ANI Pharmaceuticals and EVERSANA.

Company Details

Website: www.zendal.com/
Social

Key Metrics

Founded Year

2018

Location

Porrino, Spain

Stage

Unfunded

Ranked

43^rd among 1077 active competitors

Employee Count

253 as on Jul 31, 2026

Investment & Acquisitions

Laboratorios Maymó

Similar Companies

WuXi AppTec & 1121 more

View Zendal's full profile

Zendal has not raised any funding rounds yet.

Zendal's employee count trend

Zendal has 253 employees as of Jul 26. Here is Zendal's employee count trend over the years:

Uncover Zendal's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zendal include WuXi AppTec, ANI Pharmaceuticals and EVERSANA. Here is the list of Top 10 competitors of Zendal, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	JPMorgan Chase, Ampersand Capital & 4 others	64/100
3rd	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	North Sky Capital, ACE & Company & 2 others	63/100
4th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, Qualium Investissement ... & 2 others	63/100
5th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
7th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	60/100
8th	Curatio healthcare 2005, Chennai (India), Acquired	Provider of market research services for biopharma sector, and dermatology products for cosmetologists	$44.8M	Camel Investment Limited, ChrysCapital & 13 others	59/100
9th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	55/100
10th	Caidya 2003, Morrisville (United States), Series C	CRO focused on clinical development for phases II & III clinical trials and regulatory affair services	$373M	Qiming Venture Partners, LAV Asset Management ... & 22 others	54/100
43rd	Zendal 2018, Porrino (Spain), Unfunded	Provider of drug research & development and marketing of pharmaceutical industry	-	-	42/100